Insider Selling: Hims & Hers Health (NYSE:HIMS) Insider Sells $100,576.66 in Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Soleil Boughton sold 3,461 shares of the business’s stock in a transaction that occurred on Wednesday, October 14th. The shares were sold at an average price of $29.06, for a total value of $100,576.66. Following the completion of the sale, the insider directly owned 297,348 shares of the company’s stock, valued at approximately $8,640,932.88. The trade was a 1.15% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Soleil Boughton also recently made the following trade(s):

• On Wednesday, September 30th, Soleil Boughton sold 3,461 shares of Hims & Hers Health stock. The stock was sold at an average price of $29.17, for a total value of $100,957.37.
• On Wednesday, September 16th, Soleil Boughton sold 6,236 shares of Hims & Hers Health stock. The shares were sold at an average price of $27.86, for a total transaction of $173,734.96.
• On Wednesday, September 2nd, Soleil Boughton sold 3,458 shares of Hims & Hers Health stock. The shares were sold at an average price of $28.33, for a total transaction of $97,965.14.
• On Wednesday, August 19th, Soleil Boughton sold 25,111 shares of Hims & Hers Health stock. The shares were sold at an average price of $27.55, for a total transaction of $691,808.05.

Hims & Hers Health Stock Performance

HIMS stock opened at $28.07 on Friday. The company has a quick ratio of 0.87, a current ratio of 0.93 and a debt-to-equity ratio of 4.21. The company has a market capitalization of $6.55 billion, a price-to-earnings ratio of -44.56 and a beta of 2.44. Hims & Hers Health, Inc. has a 12 month low of $13.74 and a 12 month high of $57.45. The firm has a 50 day moving average of $29.25 and a two-hundred day moving average of $28.73.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings results on Monday, August 10th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.32). The business had revenue of $753.21 million for the quarter, compared to analyst estimates of $698.90 million. Hims & Hers Health had a negative return on equity of 6.51% and a negative net margin of 5.51%. The business’s revenue for the quarter was up 38.2% compared to the same quarter last year. During the same quarter last year, the company earned $0.17 EPS. As a group, equities analysts anticipate that Hims & Hers Health, Inc. will post -0.16 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms have commented on HIMS. TD Cowen increased their target price on shares of Hims & Hers Health from $25.00 to $30.00 and gave the stock a “hold” rating in a research report on Tuesday, August 11th. Canaccord Genuity Group boosted their price target on Hims & Hers Health from $32.00 to $40.00 and gave the stock a “buy” rating in a research report on Wednesday, July 1st. Barclays reduced their price target on Hims & Hers Health from $39.00 to $35.00 and set an “overweight” rating for the company in a research report on Friday, August 21st. Wall Street Zen upgraded Hims & Hers Health from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. Finally, JPMorgan Chase & Co. started coverage on Hims & Hers Health in a report on Friday, September 11th. They set a “neutral” rating and a $32.00 price objective on the stock. Three research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Hims & Hers Health currently has a consensus rating of “Hold” and a consensus price target of $32.43.

Hedge Funds Weigh In On Hims & Hers Health

A number of institutional investors have recently modified their holdings of HIMS. Versant Capital Management Inc lifted its stake in shares of Hims & Hers Health by 801.2% in the second quarter. Versant Capital Management Inc now owns 748 shares of the company’s stock worth $26,000 after buying an additional 665 shares during the last quarter. MassMutual Private Wealth & Trust FSB grew its stake in Hims & Hers Health by 70.0% in the 2nd quarter. MassMutual Private Wealth & Trust FSB now owns 775 shares of the company’s stock valued at $27,000 after buying an additional 319 shares during the last quarter. GK Wealth Management LLC acquired a new position in Hims & Hers Health in the 3rd quarter valued at $37,000. Compass Financial Management LLC acquired a new position in Hims & Hers Health in the 2nd quarter valued at $50,000. Finally, Bogart Wealth LLC raised its holdings in Hims & Hers Health by 180.7% in the 1st quarter. Bogart Wealth LLC now owns 2,526 shares of the company’s stock worth $52,000 after acquiring an additional 1,626 shares during the period. Institutional investors own 63.52% of the company’s stock.

Hims & Hers Health News Summary

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Potential peptide-market opportunity supports the stock. Shares rebounded from a recent slump after reports that the Trump administration and the Department of Health and Human Services are reviewing a plan that could improve access to compounded peptides, potentially opening a market estimated at $2.2 billion. Hims & Hers rises as HHS moves ahead with plan for compounding peptides
• Positive Sentiment: International expansion adds a growth catalyst. Hims & Hers launched its “Hers” women’s-health platform in Australia following its $1.15 billion Eucalyptus acquisition. The rollout expands the company’s reach in weight management, hormonal health and hair regrowth and could support longer-term international revenue growth. Hims & Hers launches Hers in Australia
• Neutral Sentiment: Insider selling provides limited signal. Insider Soleil Boughton sold 3,461 shares for approximately $100,577 under a pre-arranged Rule 10b5-1 trading plan, reducing her holdings by about 1.15%. Because the sale was scheduled in advance and she retains a substantial position, it is not necessarily a strong indicator of management’s current outlook. Hims & Hers insider stock sale
• Neutral Sentiment: Investor attention is elevated. Zacks reported increased interest in HIMS, but the article did not identify a new fundamental change in earnings, guidance or valuation. The heightened attention may increase volatility as investors monitor the legal and regulatory developments. Zacks Hims & Hers investor attention report
• Negative Sentiment: Class-action litigation is the dominant overhang. Multiple law firms publicized the same federal securities lawsuit against Hims & Hers and certain executives. The case follows an FTC complaint alleging serious business misconduct. Investors who bought shares between August 4, 2025, and July 29, 2026, have until November 2, 2026, to seek lead-plaintiff status. The litigation could increase legal expenses, reputational damage and potential liabilities. Kaplan Fox Hims & Hers class-action notice

About Hims & Hers Health

Hims & Hers Health, Inc is a direct-to-consumer telehealth company that provides access to personalized healthcare through its online platforms, Hims and Hers. The company connects consumers with licensed healthcare professionals for virtual consultations, treatment plans and prescription medications where appropriate.

Its services address a range of common health and wellness needs, including sexual health, hair loss, skincare, mental health, weight management and primary care. Hims & Hers offers branded and generic treatments, over-the-counter products, supplements and personal-care products, with services designed for both men and women.

The company was founded in 2016, launched the Hims brand in 2017 and introduced the Hers brand in 2018.